Imaging-guided delivery of RNAi for anticancer treatment

Advanced Drug Delivery Reviews

Volumn 104, Issue , 2016, Pages 44-60

  Wang, Junqing ^a,b   Mi, Peng ^a,c   Lin, Gan ^a   Wáng, Yì Xiáng J ^b   Liu, Gang ^a   Chen, Xiaoyuan ^d  

^a XIAMEN UNIVERSITY   (China)

^b Chinese University of Hong Kong   (Hong Kong)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^d NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Cancer; Gene delivery; Molecular imaging; Nanocarrier; RNA interference; siRNA; Theranostics

Indexed keywords

DISEASES; DRUG PRODUCTS; GENE TRANSFER; IMAGE PROCESSING; IMAGING TECHNIQUES; RNA;

CANCER; GENE DELIVERY; NANOCARRIERS; RNA INTERFERENCE; SIRNA; THERANOSTICS;

MOLECULAR IMAGING;

ALN VSP 02; ATU 027; CALAA 01; CYCLODEXTRIN; NANOPARTICLE; ND L 02 S 0201; SMALL INTERFERING RNA; TKM 080301; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADRENAL CORTEX CARCINOMA; ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ECHOGRAPHY; ENDOMETRIUM CANCER; ENZYME INHIBITION; EX VIVO GENE TRANSFER; FLUORESCENCE IMAGING; HUMAN; INFUSION RELATED REACTION; LIVER CANCER; LIVER METASTASIS; METASTATIC MELANOMA; MULTIMODAL IMAGING; MULTIPLE MYELOMA; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; RNA INTERFERENCE; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SOLID TUMOR; SPLEEN DISEASE; UNSPECIFIED SIDE EFFECT; DRUG DELIVERY SYSTEM; GENE THERAPY; GENETICS; NEOPLASM; TISSUE DISTRIBUTION;

DRUG DELIVERY SYSTEMS; GENETIC THERAPY; HUMANS; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TISSUE DISTRIBUTION;

EID: 84956666000     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.01.008     Document Type: Review

References (178)

1. [1] Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C., Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 (1998), 806–811.
2. [2] Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001), 494–498.
3. [3] Ginn, S.L., Alexander, I.E., Edelstein, M.L., Abedi, M.R., Wixon, J., Gene therapy clinical trials worldwide to 2012—an update. J. Gene Med. 15 (2013), 65–77.
4. [4] Thi, E.P., Mire, C.E., Ursic-Bedoya, R., Geisbert, J.B., Lee, A.C.H., Agans, K.N., Robbins, M., Deer, D.J., Fenton, K.A., MacLachlan, I., Geisbert, T.W., Marburg virus infection in nonhuman primates: therapeutic treatment by lipid-encapsulated siRNA. Sci. Transl. Med., 6, 2014, 250ra116.
5. [5] Kaiser, P.K., Symons, R.C., Shah, S.M., Quinlan, E.J., Tabandeh, H., Do, D.V., Reisen, G., Lockridge, J.A., Short, B., Guerciolini, R., Nguyen, Q.D., RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am. J. Ophthalmol. 150 (2010), 33–39, e32.
6. [6] O'Connell, R.M., Rao, D.S., Chaudhuri, A.A., Baltimore, D., Physiological and pathological roles for microRNAs in the immune system. Nat. Rev. Immunol. 10 (2010), 111–122.
7. [7] van Rooij, E., Olson, E.N., MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 11 (2012), 860–872.
8. [8] Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P.N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., Munisamy, M., Falzone, R., Harrop, J., Cehelsky, J., Bettencourt, B.R., Geissler, M., Butler, J.S., Sehgal, A., Meyers, R.E., Chen, Q., Borland, T., Hutabarat, R.M., Clausen, V.A., Alvarez, R., Fitzgerald, K., Gamba-Vitalo, C., Nochur, S.V., Vaishnaw, A.K., Sah, D.W., Gollob, J.A., Suhr, O.B., Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369 (2013), 819–829.
9. [9] Davis, M.E., Zuckerman, J.E., Choi, C.H., Seligson, D., Tolcher, A., Alabi, C.A., Yen, Y., Heidel, J.D., Ribas, A., Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464 (2010), 1067–1070.
10. [10] Shen, H., Sun, T., Ferrari, M., Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther. 19 (2012), 367–373.
11. [11] Tabernero, J., Shapiro, G.I., LoRusso, P.M., Cervantes, A., Schwartz, G.K., Weiss, G.J., Paz-Ares, L., Cho, D.C., Infante, J.R., Alsina, M., Gounder, M.M., Falzone, R., Harrop, J., White, A.C., Toudjarska, I., Bumcrot, D., Meyers, R.E., Hinkle, G., Svrzikapa, N., Hutabarat, R.M., Clausen, V.A., Cehelsky, J., Nochur, S.V., Gamba-Vitalo, C., Vaishnaw, A.K., Sah, D.W., Gollob, J.A., Burris, H.A. 3rd, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 3 (2013), 406–417.
12. [12] Alexis, F., Pridgen, E., Molnar, L.K., Farokhzad, O.C., Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5 (2008), 505–515.
13. [13] Whitehead, K.A., Langer, R., Anderson, D.G., Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8 (2009), 129–138.
14. [14] Li, W., Szoka, F.C. Jr., Lipid-based nanoparticles for nucleic acid delivery. Pharm. Res. 24 (2007), 438–449.
15. [15] Mintzer, M.A., Simanek, E.E., Nonviral vectors for gene delivery. Chem. Rev. 109 (2009), 259–302.
16. [16] Akinc, A., Zumbuehl, A., Goldberg, M., Leshchiner, E.S., Busini, V., Hossain, N., Bacallado, S.A., Nguyen, D.N., Fuller, J., Alvarez, R., Borodovsky, A., Borland, T., Constien, R., Fougerolles, A. de, Dorkin, J.R., Jayaprakash, K. Narayanannair, Jayaraman, M., John, M., Koteliansky, V., Manoharan, M., Nechev, L., Qin, J., Racie, T., Raitcheva, D., Rajeev, K.G., Sah, D.W., Soutschek, J., Toudjarska, I., Vornlocher, H.P., Zimmermann, T.S., Langer, R., Anderson, D.G., A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26 (2008), 561–569.
17. [17] Semple, S.C., Akinc, A., Chen, J., Sandhu, A.P., Mui, B.L., Cho, C.K., Sah, D.W., Stebbing, D., Crosley, E.J., Yaworski, E., Hafez, I.M., Dorkin, J.R., Qin, J., Lam, K., Rajeev, K.G., Wong, K.F., Jeffs, L.B., Nechev, L., Eisenhardt, M.L., Jayaraman, M., Kazem, M., Maier, M.A., Srinivasulu, M., Weinstein, M.J., Chen, Q., Alvarez, R., Barros, S.A., De, S., Klimuk, S.K., Borland, T., Kosovrasti, V., Cantley, W.L., Tam, Y.K., Manoharan, M., Ciufolini, M.A., Tracy, M.A., Fougerolles, A. de, MacLachlan, I., Cullis, P.R., Madden, T.D., Hope, M.J., Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28 (2010), 172–176.
18. [18] Lee, C.C., MacKay, J.A., Frechet, J.M., Szoka, F.C., Designing dendrimers for biological applications. Nat. Biotechnol. 23 (2005), 1517–1526.
19. [19] Pack, D.W., Hoffman, A.S., Pun, S., Stayton, P.S., Design and development of polymers for gene delivery. Nat. Rev. Drug Discov. 4 (2005), 581–593.
20. [20] Thomas, M., Klibanov, A.M., Non-viral gene therapy: polycation-mediated DNA delivery. Appl. Microbiol. Biotechnol. 62 (2003), 27–34.
21. [21] Mo, R.H., Zaro, J.L., Shen, W.C., Comparison of cationic and amphipathic cell penetrating peptides for siRNA delivery and efficacy. Mol. Pharm. 9 (2012), 299–309.
22. [22] Martin, M.E., Rice, K.G., Peptide-guided gene delivery. AAPS J. 9 (2007), E18–E29.
23. [23] Dassie, J.P., Liu, X.Y., Thomas, G.S., Whitaker, R.M., Thiel, K.W., Stockdale, K.R., Meyerholz, D.K., McCaffrey, A.P., McNamara, J.O. 2nd, Giangrande, P.H., Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat. Biotechnol. 27 (2009), 839–849.
24. [24] Yao, Y.D., Sun, T.M., Huang, S.Y., Dou, S., Lin, L., Chen, J.N., Ruan, J.B., Mao, C.Q., Yu, F.Y., Zeng, M.S., Zang, J.Y., Liu, Q., Su, F.X., Zhang, P., Lieberman, J., Wang, J., Song, E., Targeted delivery of PLK1-siRNA by ScFv suppresses Her2 + breast cancer growth and metastasis. Sci. Transl. Med., 4, 2012, 130ra148.
25. [25] Choi, K.Y., Silvestre, O.F., Huang, X., Hida, N., Liu, G., Ho, D.N., Lee, S., Lee, S.W., Hong, J.I., Chen, X., A nanoparticle formula for delivering siRNA or miRNAs to tumor cells in cell culture and in vivo. Nat. Protoc. 9 (2014), 1900–1915.
26. [26] Choi, K.Y., Silvestre, O.F., Huang, X., Min, K.H., Howard, G.P., Hida, N., Jin, A.J., Carvajal, N., Lee, S.W., Hong, J.I., Chen, X., Versatile RNA interference nanoplatform for systemic delivery of RNAs. ACS Nano 8 (2014), 4559–4570.
27. [27] Liu, G., Choi, K.Y., Bhirde, A., Swierczewska, M., Yin, J., Lee, S.W., Park, J.H., Hong, J.I., Xie, J., Niu, G., Kiesewetter, D.O., Lee, S., Chen, X., Sticky nanoparticles: a platform for siRNA delivery by a bis(zinc(II) dipicolylamine)-functionalized, self-assembled nanoconjugate. Angew. Chem. Int. Ed. 51 (2012), 445–449.
28. [28] Sokolova, V., Epple, M., Inorganic nanoparticles as carriers of nucleic acids into cells. Angew. Chem. Int. Ed. Engl. 47 (2008), 1382–1395.
29. [29] Afonin, K.A., Viard, M., Koyfman, A.Y., Martins, A.N., Kasprzak, W.K., Panigaj, M., Desai, R., Santhanam, A., Grabow, W.W., Jaeger, L., Heldman, E., Reiser, J., Chiu, W., Freed, E.O., Shapiro, B.A., Multifunctional RNA nanoparticles. Nano Lett. 14 (2014), 5662–5671.
30. [30] Cui, D.X., Zhang, C.L., Liu, B., Shu, Y., Du, T., Shu, D., Wang, K., Dai, F.P., Liu, Y.L., Li, C., Pan, F., Yang, Y.M., Ni, J., Li, H., Brand-Saberi, B., Guo, P.X., Regression of gastric cancer by systemic injection of RNA nanoparticles carrying both ligand and siRNA. Sci. Rep., 5, 2015, e10726.
31. [31] Lee, H., Lytton-Jean, A.K.R., Chen, Y., Love, K.T., Park, A.I., Karagiannis, E.D., Sehgal, A., Querbes, W., Zurenko, C.S., Jayaraman, M., Peng, C.G., Charisse, K., Borodovsky, A., Manoharan, M., Donahoe, J.S., Truelove, J., Nahrendorf, M., Langer, R., Anderson, D.G., Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 7 (2012), 389–393.
32. [32] Rychahou, P., Haque, F., Shu, Y., Zaytseva, Y., Weiss, H.L., Lee, E.Y., Mustain, W., Valentino, J., Guo, P., Evers, B.M., Delivery of RNA nanoparticles into colorectal cancer metastases following systemic administration. ACS Nano 9 (2015), 1108–1116.
33. [33] Shu, D., Li, H., Shu, Y., Xiong, G., Carson, W.E. 3rd, Haque, F., Xu, R., Guo, P., Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology. ACS Nano 9 (2015), 9731–9740.
34. [34] Haussecker, D., Current issues of RNAi therapeutics delivery and development. J. Control. Release 195 (2014), 49–54.
35. [35] Wang, J., Lu, Z., Wientjes, M.G., Au, J.L.S., Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 12 (2010), 492–503.
36. [36] Hornung, V., Guenthner-Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A., Manoharan, M., Akira, S., de Fougerolles, A., Endres, S., Hartmann, G., Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11 (2005), 263–270.
37. [37] Judge, A.D., Sood, V., Shaw, J.R., Fang, D., McClintock, K., MacLachlan, I., Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23 (2005), 457–462.
38. [38] Jackson, A.L., Burchard, J., Schelter, J., Chau, B.N., Cleary, M., Lim, L., Linsley, P.S., Widespread siRNA “off-target” transcript silencing mediated by seed region sequence complementarity. RNA 12 (2006), 1179–1187.
39. [39] Hong, H., Zhang, Y., Cai, W.B., In vivo imaging of RNA Interference. J. Nucl. Med. 51 (2010), 169–172.
40. [40] Willmann, J.K., van Bruggen, N., Dinkelborg, L.M., Gambhir, S.S., Molecular imaging in drug development. Nat. Rev. Drug Discov. 7 (2008), 591–607.
41. [41] Wu, S.Y., Lopez-Berestein, G., Calin, G.A., Sood, A.K., RNAi therapies: drugging the undruggable. Sci. Transl. Med. 6 (2014), 240–247.
42. [42] Contag, C.H., Bachmann, M.H., Advances in in vivo bioluminescence imaging of gene expression. Annu. Rev. Biomed. Eng. 4 (2002), 235–260.
43. [43] Wang, F., Song, X., Li, X., Xin, J., Wang, S., Yang, W., Wang, J., Wu, K., Chen, X., Liang, J., Tian, J., Cao, F., Noninvasive visualization of microRNA-16 in the chemoresistance of gastric cancer using a dual reporter gene imaging system. PLoS ONE, 8, 2013, e61792.
44. [44] Huang, X., Lee, S., Chen, X., Design of “smart” probes for optical imaging of apoptosis. Am. J. Nucl. Med. Mol Imaging 1 (2011), 3–17.
45. [45] Sosnovik, D.E., Weissleder, R., Emerging concepts in molecular MRI. Curr. Opin. Biotechnol. 18 (2007), 4–10.
46. [46] Alauddin, M.M., Positron emission tomography (PET) imaging with (18)F-based radiotracers. Am. J. Nucl. Med. Mol Imaging. 2 (2012), 55–76.
47. [47] Bhargava, P., He, G., Samarghandi, A., Delpassand, E.S., Pictorial review of SPECT/CT imaging applications in clinical nuclear medicine. Am. J. Nucl. Med. Mol Imaging. 2 (2012), 221–231.
48. [48] Dayton, P.A., Rychak, J.J., Molecular ultrasound imaging using microbubble contrast agents. Front. Biosci. 12 (2007), 5124–5142.
49. [49] Pai, S.I., Lin, Y.Y., Macaes, B., Meneshian, A., Hung, C.F., Wu, T.C., Prospects of RNA interference therapy for cancer. Gene Ther. 13 (2006), 464–477.
50. [50] Rao, D.D., Wang, Z.H., Senzer, N., Nemunaitis, J., RNA Interference and personalized cancer therapy. Discov. Med. 81 (2013), 101–110.
51. [51] M.D.A.C. Center, EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial. https://clinicaltrials.gov/ct2/show/NCT01591356?term=NCT01591356, 2012.
52. [52] C.C.C.o.W.F. University, A Phase 1, Open-Label, Dose-Ranging Study to Assess the Safety and Immunologic Activity of APN401. https://clinicaltrials.gov/ct2/show/NCT02166255, 2014.
53. [53] S. Pruitt, Phase I Study of Active Immunotherapy of Metastatic Melanoma with Mature Autologous Dendritic Cells Transfected with Tumor Antigen RNA and Small Inhibitory RNAs to Alter Proteasomal Antigen Processing. https://clinicaltrials.gov/ct2/show/NCT00672542, 2008.
54. [54] S.T. GmbH, A Prospective, Open-label, Single Center, Dose Finding Phase I-Study with Atu027 (an siRNA Formulation) in Subjects with Advanced Solid Cancer. https://clinicaltrials.gov/ct2/show/NCT00938574, 2009.
55. [55] S. Ltd, Phase I—Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas. https://clinicaltrials.gov/ct2/show/NCT01188785, 2010.
56. [56] N.C.I. (NCI), A Phase 1 Dose Escalation Study of Hepatic Intra-Arterial Administration of TKM 080301 (Lipid Nanoparticles Containing siRNA Against the PLK1 Gene Product) in Patients with Colorectal, Pancreas, Gastric, Breast, Ovarian and Esophageal Cancers with Hepatic. https://clinicaltrials.gov/ct2/show/NCT01437007, 2011.
57. [57] N.D. Corporation, A Phase 1b/2, Open Label, Randomized, Repeat Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Biological Activity, and Pharmacokinetics of ND-L02-s0201 Injection, a Vitamin A-coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Subjects with Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4). https://clinicaltrials.gov/ct2/show/NCT02227459, 2014.
58. [58] I. Dicerna Pharmaceuticals, Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma. https://clinicaltrials.gov/ct2/show/NCT02110563, 2014.
59. [59] C. Pharmaceuticals, A Phase I, Dose-Escalating Study of the Safety of Intravenous CALAA-01 in Adults with Solid Tumors Refractory to Standard-of-Care Therapies. https://clinicaltrials.gov/ct2/show/NCT00689065, 2008.
60. [60] T.P. Corporation, A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients with Advanced Solid Tumors. https://clinicaltrials.gov/ct2/show/NCT01262235, 2010.
61. [61] A. Pharmaceuticals, A Multi-Center, Open Label, Phase 1 Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 in Patients with Advanced Solid Tumors with Liver Involvement. https://clinicaltrials.gov/ct2/show/NCT00882180, 2009.
62. [62] A. Pharmaceuticals, A Multi-center, Open-Label, Extension Study of ALN-VSP02 in Cancer Patients Who Have Responded to ALN-VSP02 Treatment. https://clinicaltrials.gov/ct2/show/NCT01158079, 2009.
63. [63] Aleku, M., Schulz, P., Keil, O., Santel, A., Schaeper, U., Dieckhoff, B., Janke, O., Endruschat, J., Durieux, B., Roder, N., Loffler, K., Lange, C., Fechtner, M., Mopert, K., Fisch, G., Dames, S., Arnold, W., Jochims, K., Giese, K., Wiedenmann, B., Scholz, A., Kaufmann, J., Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res. 68 (2008), 9788–9798.
64. [64] Santel, A., Aleku, M., Roder, N., Mopert, K., Durieux, B., Janke, O., Keil, O., Endruschat, J., Dames, S., Lange, C., Eisermann, M., Loffler, K., Fechtner, M., Fisch, G., Vank, C., Schaeper, U., Giese, K., Kaufmann, J., Atu027 prevents pulmonary metastasis in experimental and spontaneous mouse metastasis models. Clin. Cancer Res. 16 (2010), 5469–5480.
65. [65] Leenders, F., Mopert, K., Schmiedeknecht, A., Santel, A., Czauderna, F., Aleku, M., Penschuck, S., Dames, S., Sternberger, M., Rohl, T., Wellmann, A., Arnold, W., Giese, K., Kaufmann, J., Klippel, A., PKN3 is required for malignant prostate cell growth downstream of activated PI 3-kinase. EMBO J. 23 (2004), 3303–3313.
66. [66] Strumberg, D., Schultheis, B., Traugott, U., Vank, C., Santel, A., Keil, O., Giese, K., Kaufmann, J., Drevs, J., Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int. J. Clin. Pharmacol. Ther. 50 (2012), 76–78.
67. [67] Schultheis, B., Strumberg, D., Santel, A., Vank, C., Gebhardt, F., Keil, O., Lange, C., Giese, K., Kaufmann, J., Khan, M., Drevs, J., First-in-human phase I study of the liposomal RNA Interference therapeutic Atu027 in patients with advanced solid tumors. J. Clin. Oncol. 32 (2014), 4141–4148.
68. [68] Blangy, A., Lane, H.A., d'Herin, P., Harper, M., Kress, M., Nigg, E.A., Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 83 (1995), 1159–1169.
69. [69] Itakura, J., Ishiwata, T., Shen, B., Kornmann, M., Korc, M., Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int. J. Cancer 85 (2000), 27–34.
70. [70] Boocock, C.A., Charnockjones, D.S., Sharkey, A.M., Mclaren, J., Barker, P.J., Wright, K.A., Twentyman, P.R., Smith, S.K., Expression of vascular endothelial growth-factor and its receptors Flt and Kdr in ovarian-carcinoma. J. Natl. Cancer Inst. 87 (1995), 506–516.
71. [71] Ferrara, N., Gerber, H.P., LeCouter, J., The biology of VEGF and its receptors. Nat. Med. 9 (2003), 669–676.
72. [72] Duxbury, M.S., Ito, H., Zinner, M.J., Ashley, S.W., Whang, E.E., RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23 (2004), 1539–1548.
73. [73] Wang, Y.X., Ng, C.K., The impact of quantitative imaging in medicine and surgery: charting our course for the future. Quant. Imaging. Med. Surg. 1 (2011), 1–3.
74. [74] Tracy Zimmermann, V.K., Harrop, Jamie, Chan, Amy, Chiesa, Joseph, Peters, Gary, Falzone, Rick, Cehelsky, Jeffrey, Nochur, Saraswathy, Vaishnaw, Akshay, Gollob, Jared, Phase I First-in-Human Trial of ALN-TTRsc, a Novel RNA Interference Therapeutic for the Treatment of Familial Amyloidotic Cardiomyopathy (FAC). http://www.alnylam.com/web/wp-content/uploads/2013/09/ALN-TTRsc-PhI-HFSA-Poster-Sep2013.pdf, 2013.
75. [75] Buyens, K., De Smedt, S.C., Braeckmans, K., Demeester, J., Peeters, L., van Grunsven, L.A., du Jeu, X.D., Sawant, R., Torchilin, V., Farkasova, K., Ogris, M., Sanders, N.N., Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. J. Control. Release 158 (2012), 362–370.
76. [76] Kanasty, R., Dorkin, J.R., Vegas, A., Anderson, D., Delivery materials for siRNA therapeutics. Nat. Mater. 12 (2013), 967–977.
77. [77] Oh, Y.K., Park, T.G., siRNA delivery systems for cancer treatment. Adv. Drug Deliv. Rev. 61 (2009), 850–862.
78. [78] Yin, H., Kanasty, R.L., Eltoukhy, A.A., Vegas, A.J., Dorkin, J.R., Anderson, D.G., Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15 (2014), 541–555.
79. [79] Zhang, P., Chen, Y., Zeng, Y., Shen, C., Li, R., Guo, Z., Li, S., Zheng, Q., Chu, C., Wang, Z., Zheng, Z., Tian, R., Ge, S., Zhang, X., Xia, N.S., Liu, G., Chen, X., Virus-mimetic nanovesicles as a versatile antigen-delivery system. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), E6129–E6138.
80. [80] Kobayashi, H., Watanabe, R., Choyke, P.L., Improving conventional enhanced permeability and retention (EPR) effects; what Is the appropriate Target?. Theranostics. 4 (2014), 81–89.
81. [81] Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer-chemotherapy—mechanism of tumoritropic accumulation of proteins and the antitumor agent Smancs. Cancer Res. 46 (1986), 6387–6392.
82. [82] Moghimi, S.M., Hunter, A.C., Murray, J.C., Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53 (2001), 283–318.
83. [83] Cho, K.J., Wang, X., Nie, S.M., Chen, Z., Shin, D.M., Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 14 (2008), 1310–1316.
84. [84] van Vlerken, L.E., Vyas, T.K., Amiji, M.M., Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res. 24 (2007), 1405–1414.
85. [85] Maclachlan, I., Cullis, P., Diffusible-PEG-lipid stabilized plasmid lipid particles. Adv. Genet., 2005, 157–188 53pa.
86. [86] Vaupel, P., Kallinowski, F., Okunieff, P., Blood-flow, oxygen and nutrient supply, and metabolic microenvironment of human-tumors—a review. Cancer Res. 49 (1989), 6449–6465.
87. [87] Li, L., Wang, R., Wilcox, D., Zhao, X., Song, J., Lin, X., Kohlbrenner, W.M., Fesik, S.W., Shen, Y., Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery. Gene Ther. 19 (2012), 775–780.
88. [88] Huang, K., Ma, H., Liu, J., Huo, S., Kumar, A., Wei, T., Zhang, X., Jin, S., Gan, Y., Wang, P.C., He, S., Zhang, X., Liang, X.J., Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano 6 (2012), 4483–4493.
89. [89] Cunha, L., Szigeti, K., Mathe, D., Metello, L.F., The role of molecular imaging in modern drug development. Drug Discov. Today 19 (2014), 936–948.
90. [90] Meade, B.R., Dowdy, S.F., Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv. Drug Deliv. Rev. 59 (2007), 134–140.
91. [91] Rozema, D.B., Lewis, D.L., Wakefield, D.H., Wong, S.C., Klein, J.J., Roesch, P.L., Bertin, S.L., Reppen, T.W., Chu, Q., Blokhin, A.V., Hagstrom, J.E., Wolff, J.A., Dynamic polyconjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 12982–12987.
92. [92] Cardoso, A.L., Simoes, S., de Almeida, L.P., Pelisek, J., Culmsee, C., Wagner, E., Pedroso de Lima, M.C., siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing. J. Gene Med. 9 (2007), 170–183.
93. [93] Chu, T.C., Twu, K.Y., Ellington, A.D., Levy, M., Aptamer mediated siRNA delivery. Nucleic Acids Res., 34, 2006, e73.
94. [94] Lorenzer, C., Dirin, M., Winkler, A.M., Baumann, V., Winkler, J., Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J. Control. Release 203 (2015), 1–15.
95. [95] Gruenberg, J., van der Goot, F.G., Mechanisms of pathogen entry through the endosomal compartments. Nat. Rev. Mol. Cell Biol. 7 (2006), 495–504.
96. [96] Sonawane, N.D., Szoka, F.C. Jr., Verkman, A.S., Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J. Biol. Chem. 278 (2003), 44826–44831.
97. [97] Boussif, O., Lezoualc'h, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B., Behr, J.P., A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 92 (1995), 7297–7301.
98. [98] Qiu, S., Adema, C.M., Lane, T., A computational study of off-target effects of RNA interference. Nucleic Acids Res. 33 (2005), 1834–1847.
99. [99] Goodchild, A., Nopper, N., King, A., Doan, T., Tanudji, M., Arndt, G.M., Poidinger, M., Rivory, L.P., Passioura, T., Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol., 10, 2009, 40.
100. [100] Judge, A.D., Sood, V., Shaw, J.R., Fang, D., McClintock, K., MacLachlan, I., Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat. Biotechnol. 23 (2005), 457–462.
101. [101] Sioud, M., Does the understanding of immune activation by RNA predict the design of safe siRNAs?. Front. Biosci. 13 (2008), 4379–4392.
102. [102] Sevick-Muraca, E.M., Houston, J.P., Gurfinkel, M., Fluorescence-enhanced, near infrared diagnostic imaging with contrast agents. Curr. Opin. Chem. Biol. 6 (2002), 642–650.
103. [103] Frangioni, J.V., In vivo near-infrared fluorescence imaging. Curr. Opin. Chem. Biol. 7 (2003), 626–634.
104. [104] Zanzonico, P., Noninvasive imaging for supporting basic research. Small Animal Imaging: Basics and Practical Guide, 2011, 3–16.
105. [105] Leblond, F., Davis, S.C., Valdés, P.A., Pogue, B.W., Pre-clinical whole-body fluorescence imaging: review of instruments, methods and applications. J. Photochem. Photobiol., B 98 (2010), 77–94.
106. [106] Guo, Z., Park, S., Yoon, J., Shin, I., Recent progress in the development of near-infrared fluorescent probes for bioimaging applications. Chem. Soc. Rev. 43 (2014), 16–29.
107. [107] Kim, S.H., Jeong, J.H., Lee, S.H., Kim, S.W., Park, T.G., Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release 129 (2008), 107–116.
108. [108] Gilleron, J., Querbes, W., Zeigerer, A., Borodovsky, A., Marsico, G., Schubert, U., Manygoats, K., Seifert, S., Andree, C., Stoter, M., Epstein-Barash, H., Zhang, L., Koteliansky, V., Fitzgerald, K., Fava, E., Bickle, M., Kalaidzidis, Y., Akinc, A., Maier, M., Zerial, M., Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31 (2013), 638–646.
109. [109] Chang, E., Zhu, M.Q., Drezek, R., Novel siRNA-based molecular beacons for dual imaging and therapy. Biotechnol. J. 2 (2007), 422–425.
110. [110] Christie, R.J., Matsumoto, Y., Miyata, K., Nomoto, T., Fukushima, S., Osada, K., Halnaut, J., Pittella, F., Kim, H.J., Nishiyama, N., Kataoka, K., Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano 6 (2012), 5174–5189.
111. [111] Christie, R.J., Miyata, K., Matsumoto, Y., Nomoto, T., Menasco, D., Lai, T.C., Pennisi, M., Osada, K., Fukushima, S., Nishiyama, N., Yamasaki, Y., Kataoka, K., Effect of polymer structure on micelles formed between siRNA and cationic block copolymer comprising thiols and amidines. Biomacromolecules 12 (2011), 3174–3185.
112. [112] Oe, Y., Christie, R.J., Naito, M., Low, S.A., Fukushima, S., Toh, K., Miura, Y., Matsumoto, Y., Nishiyama, N., Miyata, K., Kataoka, K., Actively-targeted polyion complex micelles stabilized by cholesterol and disulfide cross-linking for systemic delivery of siRNA to solid tumors. Biomaterials 35 (2014), 7887–7895.
113. [113] Chen, A.A., Derfus, A.M., Khetani, S.R., Bhatia, S.N., Quantum dots to monitor RNAi delivery and improve gene silencing. Nucleic Acids Res., 33, 2005, e190.
114. [114] Wang, J., Zhang, P., Huang, C., Liu, G., Leung, K.C., Wang, Y.X., High performance photoluminescent carbon dots for In Vitro and In vivo bioimaging: effect of nitrogen doping ratios. Langmuir 31 (2015), 8063–8073.
115. [115] Jiang, S., Zhang, Y., Lim, K.M., Sim, E.K.W., Ye, L., NIR-to-visible upconversion nanoparticles for fluorescent labeling and targeted delivery of siRNA. Nanotechnology, 20, 2009, e155101.
116. [116] Jung, J., Solanki, A., Memoli, K.A., Kamei, K., Kim, H., Drahl, M.A., Williams, L.J., Tseng, H.R., Lee, K., Selective inhibition of human brain tumor cells through multifunctional quantum-dot-based siRNA delivery. Angew. Chem. Int. Ed. 49 (2010), 103–107.
117. [117] Wang, J., Liu, G., Leung, K.C., Loffroy, R., Lu, P.X., Wang, Y.X., Opportunities and challenges of fluorescent carbon dots in translational optical imaging. Curr. Pharm. Des. 21 (2015), 5401–5416.
118. [118] Wang, L., Wang, X., Bhirde, A., Cao, J., Zeng, Y., Huang, X., Sun, Y., Liu, G., Chen, X., Carbon-dot-based two-photon visible nanocarriers for safe and highly efficient delivery of siRNA and DNA. Adv. Healthc. Mater. 3 (2014), 1203–1209.
119. [119] Chatterjee, D.K., Gnanasammandhan, Y., Fau-Zhang, Mk, Zhang, Y., Small upconverting fluorescent nanoparticles for biomedical applications. Small 6 (2010), 2781–2795.
120. [120] Wang, L., Liu, J., Dai, Y., Yang, Q., Zhang, Y., Yang, P., Cheng, Z., Lian, H., Li, C., Hou, Z., Ma, P., Lin, J., Efficient gene delivery and multimodal imaging by lanthanide-based upconversion nanoparticles. Langmuir 30 (2014), 13042–13051.
121. [121] Nayak, T.R., Krasteva, L.K., Cai, W., Multimodality imaging of RNA Interference. Curr. Med. Chem. 20 (2013), 3664–3675.
122. [122] McCaffrey, A.P., Meuse, L., Pham, T.T., Conklin, D.S., Hannon, G.J., Kay, M.A., RNA interference in adult mice. Nature 418 (2002), 38–39.
123. [123] Lewis, D.L., Hagstrom, J.E., Loomis, A.G., Wolff, J.A., Herweijer, H., Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 32 (2002), 107–108.
124. [124] Pichler, A., Zelcer, N., Prior, J.L., Kuil, A.J., Piwnica-Worms, D., In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein. Clin. Cancer Res. 11 (2005), 4487–4494.
125. [125] Pittella, F., Cabral, H., Maeda, Y., Mi, P., Watanabe, S., Takemoto, H., Kim, H.J., Nishiyama, N., Miyata, K., Kataoka, K., Systemic siRNA delivery to a spontaneous pancreatic tumor model in transgenic mice by PEGylated calcium phosphate hybrid micelles. J. Control. Release 178 (2014), 18–24.
126. [126] Bartlett, D.W., Davis, M.E., Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging. Nucleic Acids Res. 34 (2006), 322–333.
127. [127] Kim, S.H., Mok, H., Jeong, J.H., Kim, S.W., Park, T.G., Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. Bioconjug. Chem. 17 (2006), 241–244.
128. [128] Huschka, R., Barhoumi, A., Liu, Q., Roth, J.A., Ji, L., Halas, N.J., Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA. ACS Nano 6 (2012), 7681–7691.
129. [129] James, M.L., Gambhir, S.S., A molecular imaging primer: modalities, imaging agents, and applications. Physiol. Rev. 92 (2012), 897–965.
130. [130] Phelps, M.E., Positron emission tomography provides molecular imaging of biological processes. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 9226–9233.
131. [131] Ziegler, S.I., Positron emission tomography: principles, technology, and recent developments. Nucl. Phys. A. 752 (2005), 679c–687c.
132. [132] Lammers, T., Aime, S., Hennink, W.E., Storm, G., Kiessling, F., Theranostic nanomedicine. Acc. Chem. Res. 44 (2011), 1029–1038.
133. [133] Lu, W., Zhang, G., Zhang, R., Flores, L.G. 2nd, Huang, Q., Gelovani, J.G., Li, C., Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res. 70 (2010), 3177–3188.
134. [134] Nayak, T.R., Krasteva, L.K., Cai, W., Multimodality imaging of RNA interference. Curr. Med. Chem. 20 (2013), 3664–3675.
135. [135] Hatanaka, K., Asai, T., Koide, H., Kenjo, E., Tsuzuku, T., Harada, N., Tsukada, H., Oku, N., Development of double-stranded siRNA labeling method using positron emitter and its in vivo trafficking analyzed by positron emission tomography. Bioconjug. Chem. 21 (2010), 756–763.
136. [136] Lu, F.M., Yuan, Z., PET/SPECT molecular imaging in clinical neuroscience: recent advances in the investigation of CNS diseases. Quant. Imaging. Med. Surg. 5 (2015), 433–447.
137. [137] Liu, N., Ding, H., Vanderheyden, J.L., Zhu, Z., Zhang, Y., Radiolabeling small RNA with technetium-99 m for visualizing cellular delivery and mouse biodistribution. Nucl. Med. Biol. 34 (2007), 399–404.
138. [138] Merkel, O.M., Librizzi, D., Pfestroff, A., Schurrat, T., Behe, M., Kissel, T., In vivo SPECT and real-time gamma camera imaging of biodistribution and pharmacokinetics of siRNA delivery using an optimized radiolabeling and purification procedure. Bioconjug. Chem. 20 (2009), 174–182.
139. [139] Faulkner, W., Basic Principles of MRI. OutSource, 1996.
140. [140] Wang, Y.X., Superparamagnetic iron oxide based MRI contrast agents: current status of clinical application. Quant. Imaging. Med. Surg. 1 (2011), 35–40.
141. [141] Mok, H., Veiseh, O., Fang, C., Kievit, F.M., Wang, F.Y., Park, J.O., Zhang, M., pH-sensitive siRNA nanovector for targeted gene silencing and cytotoxic effect in cancer cells. Mol. Pharm. 7 (2010), 1930–1939.
142. [142] Shen, M., Gong, F., Pang, P., Zhu, K., Meng, X., Wu, C., Wang, J., Shan, H., Shuai, X., An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma. Int. J. Nanomedicine 7 (2012), 3319–3332.
143. [143] Li, C., Penet, M.F., Wildes, F., Takagi, T., Chen, Z.H., Winnard, P.T., Artemov, D., Bhujwalla, Z.M., Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. ACS Nano 4 (2010), 6707–6716.
144. [144] Bae, K.H., Lee, K., Kim, C., Park, T.G., Surface functionalized hollow manganese oxide nanoparticles for cancer targeted siRNA delivery and magnetic resonance imaging. Biomaterials 32 (2011), 176–184.
145. [145] Zhou, Z., Huang, D., Bao, J., Chen, Q., Liu, G., Chen, Z., Chen, X., Gao, J., A synergistically enhanced T(1)–T(2) dual-modal contrast agent. Adv. Mater. 24 (2012), 6223–6228.
146. [146] Wang, X., Zhou, Z., Wang, Z., Xue, Y., Zeng, Y., Gao, J., Zhu, L., Zhang, X., Liu, G., Chen, X., Gadolinium embedded iron oxide nanoclusters as T1–T2 dual-modal MRI-visible vectors for safe and efficient siRNA delivery. Nanoscale. 5 (2013), 8098–8104.
147. [147] Liang, H.D., Blomley, M.J.K., The role of ultrasound in molecular imaging. Br. J. Radiol. 76 (2003), S140–S150.
148. [148] Shim, M.S., Kwon, Y.J., Stimuli-responsive polymers and nanomaterials for gene delivery and imaging applications. Adv. Drug Deliv. Rev. 64 (2012), 1046–1059.
149. [149] Unger, E., Porter, T., Lindner, J., Grayburn, P., Cardiovascular drug delivery with ultrasound and microbubbles. Adv. Drug Deliv. Rev. 72 (2014), 110–126.
150. [150] Martin, K.H., Dayton, P.A., Current status and prospects for microbubbles in ultrasound theranostics. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 5 (2013), 329–345.
151. [151] Florinas, S., Kim, J., Nam, K., Janat-Amsbury, M.M., Kim, S.W., Ultrasound-assisted siRNA delivery via arginine-grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment. J. Control. Release 183 (2014), 1–8.
152. [152] Vandenbroucke, R.E., Lentacker, I., Demeester, J., De Smedt, S.C., Sanders, N.N., Ultrasound assisted siRNA delivery using PEG-siPlex loaded microbubbles. J. Control. Release 126 (2008), 265–273.
153. [153] Liu, Y., Miyoshi, H., Nakamura, M., Encapsulated ultrasound microbubbles: therapeutic application in drug/gene delivery. J. Control. Release 114 (2006), 89–99.
154. [154] Chen, C.C., Sheeran, P.S., Wu, S.Y., Olumolade, O.O., Dayton, P.A., Konofagou, E.E., Targeted drug delivery with focused ultrasound-induced blood–brain barrier opening using acoustically-activated nanodroplets. J. Control. Release 172 (2013), 795–804.
155. [155] Cheng, X., Li, H., Chen, Y., Luo, B., Liu, X., Liu, W., Xu, H., Yang, X., Ultrasound-triggered phase transition sensitive magnetic fluorescent nanodroplets as a multimodal imaging contrast agent in rat and mouse model. PLoS ONE, 8, 2013, e85003.
156. [156] Dayton, P.A., Zhao, S., Bloch, S.H., Schumann, P., Penrose, K., Matsunaga, T.O., Zutshi, R., Doinikov, A., Ferrara, K.W., Application of ultrasound to selectively localize nanodroplets for targeted imaging and therapy. Mol. Imaging 5 (2006), 160–174.
157. [157] Jian, J., Liu, C., Gong, Y., Su, L., Zhang, B., Wang, Z., Wang, D., Zhou, Y., Xu, F., Li, P., Zheng, Y., Song, L., Zhou, X., India ink incorporated multifunctional phase-transition nanodroplets for photoacoustic/ultrasound dual-modality imaging and photoacoustic effect based tumor therapy. Theranostics. 4 (2014), 1026–1038.
158. [158] Horie, S., Watanabe, Y., Ono, M., Mori, S., Kodama, T., Evaluation of antitumor effects following tumor necrosis factor-alpha gene delivery using nanobubbles and ultrasound. Cancer Sci. 102 (2011), 2082–2089.
159. [159] Wang, C.H., Huang, Y.F., Yeh, C.K., Aptamer-conjugated nanobubbles for targeted ultrasound molecular imaging. Langmuir 27 (2011), 6971–6976.
160. [160] Yin, T., Wang, P., Li, J., Wang, Y., Zheng, B., Zheng, R., Cheng, D., Shuai, X., Tumor-penetrating codelivery of siRNA and paclitaxel with ultrasound-responsive nanobubbles hetero-assembled from polymeric micelles and liposomes. Biomaterials 35 (2014), 5932–5943.
161. [161] Chen, Z., Liang, K., Liu, J., Xie, M., Wang, X., Lu, Q., Zhang, J., Fang, L., Enhancement of survivin gene downregulation and cell apoptosis by a novel combination: liposome microbubbles and ultrasound exposure. Med. Oncol. 26 (2009), 491–500.
162. [162] Castle, J., Butts, M., Healey, A., Kent, K., Marino, M., Feinstein, S.B., Ultrasound-mediated targeted drug delivery: recent success and remaining challenges. Am. J. Physiol. Heart Circ. Physiol. 304 (2013), H350–H357.
163. [163] Kaneko, O.F., Willmann, J.K., Ultrasound for molecular imaging and therapy in cancer. Quant. Imaging. Med. Surg. 2 (2012), 87–97.
164. [164] Son, S., Min, H.S., You, D.G., Kim, B.S., Kwon, I.C., Echogenic nanoparticles for ultrasound technologies: evolution from diagnostic imaging modality to multimodal theranostic agent. Nano Today 9 (2014), 525–540.
165. [165] Sboros, V., Response of contrast agents to ultrasound. Adv. Drug Deliv. Rev. 60 (2008), 1117–1136.
166. [166] Carson, A.R., McTiernan, C.F., Lavery, L., Grata, M., Leng, X., Wang, J., Chen, X., Villanueva, F.S., Ultrasound-targeted microbubble destruction to deliver siRNA cancer therapy. Cancer Res. 72 (2012), 6191–6199.
167. [167] Zhou, Q.-L., Chen, Z.-Y., Wang, Y.-X., Yang, F., Lin, Y., Liao, Y.-Y., Ultrasound-mediated local drug and gene delivery using nanocarriers. Biomed. Res. Int., 2014, e963891.
168. [168] Yin, T., Wang, P., Li, J., Zheng, R., Zheng, B., Cheng, D., Li, R., Lai, J., Shuai, X., Ultrasound-sensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas. Biomaterials 34 (2013), 4532–4543.
169. [169] Lee, D.E., Koo, H., Sun, I.C., Ryu, J.H., Kim, K., Kwon, I.C., Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem. Soc. Rev. 41 (2012), 2656–2672.
170. [170] Choi, H.S., Frangioni, J.V., Nanoparticles for biomedical imaging: fundamentals of clinical translation. Mol. Imaging 9 (2010), 291–310.
171. [171] Louie, A.Y., Multimodality imaging probes: design and challenges. Chem. Rev. 110 (2010), 3146–3195.
172. [172] Boerman, O.C., Oyen, W.J.G., Multimodality probes: amphibian cars for molecular imaging. J. Nucl. Med. 49 (2008), 1213–1214.
173. [173] Idee, J.M., Louguet, S., Ballet, S., Corot, C., Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint. Quant. Imaging. Med. Surg. 3 (2013), 292–297.
174. [174] Wang, Y.X., Physical scientists research biomedicine: a call for caution. Chin. J. Cancer Res. 27 (2015), 94–95.
175. [175] Medarova, Z., Pham, W., Farrar, C., Petkova, V., Moore, A., In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 13 (2007), 372–377.
176. [176] Mikhaylova, M., Stasinopoulos, I., Kato, Y., Artemov, D., Bhujwalla, Z.M., Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA. Cancer Gene Ther. 16 (2009), 217–226.
177. [177] Bartlett, D.W., Su, H., Hildebrandt, I.J., Weber, W.A., Davis, M.E., Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 15549–15554.
178. [178] Wang, Y.X.J., Choi, Y., Chen, Z.Y., Laurent, S., Gibbs, S.L., Molecular imaging: from bench to clinic. Biomed. Res. Int., 2014, 2014, 357258.